Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

摘要: Delivering standard-dose chemotherapy on schedule is important for survival in early-stage breast cancer and non-Hodgkin's lymphoma. Trials of dose-escalated regimens, which higher-than-standard doses are used, have produced equivocal results. In contrast, dose-dense standard given with shorter (usually 14-day) intervals between cycles, been more efficacious than 21-day regimens trials both Furthermore, a course likely to cause less disruption patients' lives. Despite the evidence importance maintaining dose intensity (the amount drug administered/unit time), undertreatment patients lymphoma common. Neutropenia primary dose-limiting toxicity many it frequently managed by reductions delays that decrease intensity. Colony-stimulating factors reduce prevalence severity neutropenia its complications, their proactive use can improve adherence planned chemotherapy. The promising results indicate should be tested other chemosensitive tumors.